Cover
Cover - shares | 6 Months Ended | |
Jun. 30, 2020 | Jul. 17, 2020 | |
Document Information | ||
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Jun. 30, 2020 | |
Document Transition Report | false | |
Entity File Number | 001-35907 | |
Entity Registrant Name | IQVIA HOLDINGS INC. | |
Entity Incorporation, State | DE | |
Entity Tax Identification Number | 27-1341991 | |
Entity Address, Street | 4820 Emperor Blvd. | |
Entity Address, City | Durham | |
Entity Address, State | NC | |
Entity Address, Postal Zip Code | 27703 | |
City Area Code | 919 | |
Local Phone Number | 998-2000 | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Large Accelerated Filer | |
Entity Small Business | false | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Title of Each Class | Common Stock, par value $0.01 per share | |
Trading Symbol | IQV | |
Name of Each Exchange on which Registered | NYSE | |
Entity Common Stock, Shares Outstanding | 191,270,966 | |
Current Fiscal Year End Date | --12-31 | |
Entity Central Index Key | 0001478242 | |
Amendment Flag | false | |
Document Fiscal Year Focus | 2020 | |
Document Fiscal Period Focus | Q2 | |
Principal Executive Offices | ||
Document Information | ||
Entity Address, Street | 83 Wooster Heights Road | |
Entity Address, City | Danbury | |
Entity Address, State | CT | |
Entity Address, Postal Zip Code | 06810 | |
City Area Code | 203 | |
Local Phone Number | 448-4600 |
CONDENSED CONSOLIDATED STATEMEN
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS) (unaudited) - USD ($) shares in Millions, $ in Millions | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2020 | Jun. 30, 2019 | |
Income Statement [Abstract] | ||||
Revenues | $ 2,521 | $ 2,740 | $ 5,275 | $ 5,424 |
Costs of revenue, exclusive of depreciation and amortization | 1,704 | 1,799 | 3,528 | 3,547 |
Selling, general and administrative expenses | 431 | 436 | 838 | 855 |
Depreciation and amortization | 308 | 294 | 624 | 589 |
Restructuring costs | 16 | 14 | 30 | 26 |
Income from operations | 62 | 197 | 255 | 407 |
Interest income | (1) | (2) | (3) | (4) |
Interest expense | 108 | 114 | 214 | 224 |
Loss on extinguishment of debt | 12 | 0 | 12 | 0 |
Other (income) expense, net | (32) | 7 | (45) | 0 |
(Loss) Income before income taxes and equity in earnings of unconsolidated affiliates | (25) | 78 | 77 | 187 |
Income tax (benefit) expense | (5) | 8 | 12 | 49 |
(Loss) Income before equity in earnings of unconsolidated affiliates | (20) | 70 | 65 | 138 |
Equity in (loss) earnings of unconsolidated affiliates | (1) | 1 | 5 | 0 |
Net (loss) income | (21) | 71 | 70 | 138 |
Net income attributable to non-controlling interests | (2) | (11) | (11) | (20) |
Net (loss) income attributable to IQVIA Holdings Inc. | $ (23) | $ 60 | $ 59 | $ 118 |
Loss (earnings) per share attributable to common stockholders: | ||||
Basic (in dollars per share) | $ (0.12) | $ 0.31 | $ 0.31 | $ 0.60 |
Diluted (in dollars per share) | $ (0.12) | $ 0.30 | $ 0.30 | $ 0.59 |
Weighted average common shares outstanding: | ||||
Basic (in shares) | 190.9 | 196.2 | 191.3 | 196.6 |
Diluted (in shares) | 190.9 | 200.6 | 195 | 201.2 |
CONDENSED CONSOLIDATED STATEM_2
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (unaudited) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2020 | Jun. 30, 2019 | |
Statement of Comprehensive Income [Abstract] | ||||
Net (loss) income | $ (21) | $ 71 | $ 70 | $ 138 |
Comprehensive income (loss) adjustments: | ||||
Unrealized gains (losses) on derivative instruments, net of income tax (benefit) expense of $(3), $(4), $(11), $(5) | 7 | (13) | (32) | (18) |
Foreign currency translation, net of income tax (benefit) expense of $(29), $(22), $(6), $8 | 45 | 62 | (110) | 31 |
Reclassification adjustments: | ||||
(Gains) losses on derivative instruments included in net income, net of income tax expense (benefit) of $1, $—, $1, $(1) | (12) | (3) | 4 | (4) |
Comprehensive income (loss) | 19 | 117 | (68) | 147 |
Comprehensive income attributable to non-controlling interests | (1) | (10) | (6) | (20) |
Comprehensive income (loss) attributable to IQVIA Holdings Inc. | 18 | 107 | (74) | 127 |
Unrealized (losses) gains on derivative instruments, income tax {benefit) expense | 3 | 4 | (11) | (5) |
Foreign currency translation, income tax expense | (29) | (22) | (6) | 8 |
Income tax (benefit) expense | $ 1 | $ 0 | $ 1 | $ (1) |
CONDENSED CONSOLIDATED STATEM_3
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (unaudited) (Parenthetical) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2020 | Jun. 30, 2019 | |
Statement of Comprehensive Income [Abstract] | ||||
Unrealized (losses) gains on derivative instruments, income tax {benefit) expense | $ 3 | $ 4 | $ (11) | $ (5) |
Foreign currency translation, income tax expense | (29) | (22) | (6) | 8 |
Income tax (benefit) expense | $ 1 | $ 0 | $ 1 | $ (1) |
CONDENSED CONSOLIDATED BALANCE
CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($) $ in Millions | Jun. 30, 2020 | Dec. 31, 2019 |
Current assets: | ||
Cash and cash equivalents | $ 1,109 | $ 837 |
Trade accounts receivable and unbilled services, net | 2,371 | 2,582 |
Prepaid expenses | 146 | 138 |
Income taxes receivable | 53 | 56 |
Investments in debt, equity and other securities | 73 | 62 |
Other current assets and receivables | 456 | 451 |
Total current assets | 4,208 | 4,126 |
Property and equipment, net | 444 | 458 |
Operating lease right-of-use assets | 502 | 496 |
Investments in debt, equity and other securities | 80 | 65 |
Investments in unconsolidated affiliates | 73 | 87 |
Goodwill | 12,133 | 12,159 |
Other identifiable intangibles, net | 5,262 | 5,514 |
Deferred income taxes | 123 | 119 |
Deposits and other assets | 358 | 227 |
Total assets | 23,183 | 23,251 |
Current liabilities: | ||
Accounts payable and accrued expenses | 2,295 | 2,512 |
Unearned income | 1,061 | 1,014 |
Income taxes payable | 102 | 108 |
Current portion of long-term debt | 142 | 100 |
Other current liabilities | 243 | 211 |
Total current liabilities | 3,843 | 3,945 |
Long-term debt | 11,965 | 11,545 |
Deferred income taxes | 539 | 646 |
Operating lease liabilities | 402 | 396 |
Other liabilities | 582 | 456 |
Total liabilities | 17,331 | 16,988 |
Commitments and contingencies | ||
Stockholders’ equity: | ||
Common stock and additional paid-in capital, 400.0 shares authorized at June 30, 2020 and December 31, 2019, $0.01 par value, 254.1 shares issued and 191.3 shares outstanding at June 30, 2020; 253.0 shares issued and 192.3 shares outstanding at December 31, 2019 | 11,043 | 11,049 |
Retained earnings | 1,057 | 998 |
Treasury stock, at cost, 62.8 and 60.7 shares at June 30, 2020 and December 31, 2019, respectively | (6,065) | (5,733) |
Accumulated other comprehensive loss | (444) | (311) |
Equity attributable to IQVIA Holdings Inc.’s stockholders | 5,591 | 6,003 |
Non-controlling interests | 261 | 260 |
Total stockholders’ equity | 5,852 | 6,263 |
Total liabilities and stockholders’ equity | $ 23,183 | $ 23,251 |
CONDENSED CONSOLIDATED BALANC_2
CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical) - $ / shares | Jun. 30, 2020 | Dec. 31, 2019 |
Statement of Financial Position [Abstract] | ||
Common stock, shares authorized | 400,000,000 | 400,000,000 |
Common stock, par value, usd per share | $ 0.01 | $ 0.01 |
Common stock, shares issued | 254,100,000 | 253,000,000 |
Common stock, shares outstanding | 191,300,000 | 192,300,000 |
Treasury stock, shares | 62,800,000 | 60,700,000 |
CONDENSED CONSOLIDATED STATEM_4
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($) $ in Millions | 6 Months Ended | |
Jun. 30, 2020 | Jun. 30, 2019 | |
Operating activities: | ||
Net (loss) income | $ 70 | $ 138 |
Adjustments to reconcile net income to cash provided by operating activities: | ||
Depreciation and amortization | 624 | 589 |
Amortization of debt issuance costs and discount | 8 | 6 |
Stock-based compensation | 36 | 60 |
Earnings from unconsolidated affiliates | (5) | 0 |
Gain on investments, net | (14) | (5) |
Benefit from deferred income taxes | (102) | (66) |
Changes in operating assets and liabilities: | ||
Change in accounts receivable, unbilled services and unearned income | 208 | (52) |
Change in other operating assets and liabilities | (190) | (166) |
Net cash provided by operating activities | 635 | 504 |
Investing activities: | ||
Acquisition of property, equipment and software | (283) | (296) |
Acquisition of businesses, net of cash acquired | (92) | (201) |
Purchases of marketable securities, net | (7) | (2) |
Investments in unconsolidated affiliates, net of payments received | 15 | (3) |
Investments in equity securities | (2) | (10) |
Other | 0 | 2 |
Net cash used in investing activities | (369) | (510) |
Financing activities: | ||
Proceeds from issuance of debt | 1,590 | 1,100 |
Payment of debt issuance costs | (33) | (11) |
Repayment of debt and principal payments on capital lease obligations | (755) | (50) |
Proceeds from revolving credit facility | 1,250 | 1,100 |
Repayment of revolving credit facility | (1,610) | (1,720) |
(Payments) proceeds related to employee stock option plans | (41) | |
(Payments) proceeds related to employee stock option plans | 12 | |
Repurchase of common stock | (346) | (381) |
Distributions to non-controlling interest, net | (5) | (2) |
Contingent consideration and deferred purchase price payments | (16) | (20) |
Net cash provided by financing activities | 34 | 28 |
Effect of foreign currency exchange rate changes on cash | (28) | 25 |
Increase in cash and cash equivalents | 272 | 47 |
Cash and cash equivalents at beginning of period | 837 | 891 |
Cash and cash equivalents at end of period | $ 1,109 | $ 938 |
CONDENSED CONSOLIDATED STATEM_5
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (unaudited) - USD ($) shares in Millions, $ in Millions | Total | Common Stock | Treasury Stock | Additional Paid-In Capital | Retained Earnings | Accumulated Other Comprehensive (Loss) Income | Non- controlling Interests |
Beginning balance at Dec. 31, 2018 | $ 6,954 | $ 3 | $ (4,770) | $ 10,898 | $ 807 | $ (224) | $ 240 |
Beginning Balance, Shares at Dec. 31, 2018 | 251.5 | (54) | |||||
Increase (Decrease) in Stockholders' Equity | |||||||
Issuance of common stock | 5 | 5 | |||||
Issuance of common stock, Shares | 0.7 | ||||||
Repurchase of common stock | (145) | $ (145) | |||||
Repurchase of common stock, Shares | (1) | ||||||
Stock-based compensation | 21 | 21 | |||||
Net (loss) income | 67 | 58 | 9 | ||||
Unrealized losses on derivative instruments, net of tax | (5) | (5) | |||||
Foreign currency translation, net of tax | (31) | (32) | 1 | ||||
Reclassification adjustments, net of tax | (1) | (1) | |||||
Ending balance at Mar. 31, 2019 | 6,865 | $ 3 | $ (4,915) | 10,924 | 865 | (262) | 250 |
Ending Balance, Shares at Mar. 31, 2019 | 252.2 | (55) | |||||
Beginning balance at Dec. 31, 2018 | 6,954 | $ 3 | $ (4,770) | 10,898 | 807 | (224) | 240 |
Beginning Balance, Shares at Dec. 31, 2018 | 251.5 | (54) | |||||
Increase (Decrease) in Stockholders' Equity | |||||||
Net (loss) income | 138 | ||||||
Unrealized losses on derivative instruments, net of tax | (18) | ||||||
Foreign currency translation, net of tax | 31 | ||||||
Ending balance at Jun. 30, 2019 | 6,781 | $ 3 | $ (5,151) | 10,961 | 925 | (215) | 258 |
Ending Balance, Shares at Jun. 30, 2019 | 252.6 | (56.8) | |||||
Beginning balance at Mar. 31, 2019 | 6,865 | $ 3 | $ (4,915) | 10,924 | 865 | (262) | 250 |
Beginning Balance, Shares at Mar. 31, 2019 | 252.2 | (55) | |||||
Increase (Decrease) in Stockholders' Equity | |||||||
Issuance of common stock | 8 | $ 0 | 8 | 0 | 0 | 0 | |
Issuance of common stock, Shares | 0.4 | ||||||
Repurchase of common stock | (236) | $ 0 | $ (236) | 0 | |||
Repurchase of common stock, Shares | (1.8) | ||||||
Stock-based compensation | 29 | 29 | |||||
Distributions to non-controlling interests | (2) | 0 | (2) | ||||
Net (loss) income | 71 | 60 | 11 | ||||
Unrealized losses on derivative instruments, net of tax | (13) | (13) | 0 | ||||
Foreign currency translation, net of tax | 62 | 0 | 63 | (1) | |||
Reclassification adjustments, net of tax | (3) | (3) | |||||
Ending balance at Jun. 30, 2019 | 6,781 | $ 3 | $ (5,151) | 10,961 | 925 | (215) | 258 |
Ending Balance, Shares at Jun. 30, 2019 | 252.6 | (56.8) | |||||
Beginning balance at Dec. 31, 2019 | $ 6,263 | $ 3 | $ (5,733) | 11,046 | 998 | (311) | 260 |
Beginning Balance, Shares at Dec. 31, 2019 | 192.3 | 253 | (60.7) | ||||
Increase (Decrease) in Stockholders' Equity | |||||||
Issuance of common stock | $ (44) | (44) | |||||
Issuance of common stock, Shares | 0.8 | ||||||
Repurchase of common stock | (332) | $ (332) | |||||
Repurchase of common stock, Shares | (2.1) | ||||||
Stock-based compensation | 7 | 7 | |||||
Distributions to non-controlling interests | (5) | (5) | |||||
Net (loss) income | 91 | 82 | 9 | ||||
Unrealized losses on derivative instruments, net of tax | (39) | (39) | |||||
Foreign currency translation, net of tax | (155) | (151) | (4) | ||||
Reclassification adjustments, net of tax | 16 | 16 | |||||
Ending balance at Mar. 31, 2020 | 5,802 | $ 3 | $ (6,065) | 11,009 | 1,080 | (485) | 260 |
Ending Balance, Shares at Mar. 31, 2020 | 253.8 | (62.8) | |||||
Beginning balance at Dec. 31, 2019 | $ 6,263 | $ 3 | $ (5,733) | 11,046 | 998 | (311) | 260 |
Beginning Balance, Shares at Dec. 31, 2019 | 192.3 | 253 | (60.7) | ||||
Increase (Decrease) in Stockholders' Equity | |||||||
Net (loss) income | $ 70 | ||||||
Unrealized losses on derivative instruments, net of tax | (32) | ||||||
Foreign currency translation, net of tax | (110) | ||||||
Ending balance at Jun. 30, 2020 | $ 5,852 | $ 3 | $ (6,065) | 11,040 | 1,057 | (444) | 261 |
Ending Balance, Shares at Jun. 30, 2020 | 191.3 | 254.1 | (62.8) | ||||
Beginning balance at Mar. 31, 2020 | $ 5,802 | $ 3 | $ (6,065) | 11,009 | 1,080 | (485) | 260 |
Beginning Balance, Shares at Mar. 31, 2020 | 253.8 | (62.8) | |||||
Increase (Decrease) in Stockholders' Equity | |||||||
Issuance of common stock | 1 | 1 | |||||
Issuance of common stock, Shares | 0.3 | ||||||
Stock-based compensation | 30 | 30 | |||||
Net (loss) income | (21) | (23) | 2 | ||||
Unrealized losses on derivative instruments, net of tax | 7 | 7 | |||||
Foreign currency translation, net of tax | 45 | 46 | (1) | ||||
Reclassification adjustments, net of tax | (12) | (12) | |||||
Ending balance at Jun. 30, 2020 | $ 5,852 | $ 3 | $ (6,065) | $ 11,040 | $ 1,057 | $ (444) | $ 261 |
Ending Balance, Shares at Jun. 30, 2020 | 191.3 | 254.1 | (62.8) |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 6 Months Ended |
Jun. 30, 2020 | |
Accounting Policies [Abstract] | |
Summary of Significant Accounting Policies | Summary of Significant Accounting Policies The Company IQVIA Holdings Inc. (together with its subsidiaries, the “Company” or “IQVIA”) is a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. With approximately 67,000 employees, IQVIA conducts business in more than 100 countries. Unaudited Interim Financial Information The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair statement of the Company’s financial condition and results of operations have been included. Operating results for the periods presented are not necessarily indicative of the results that may be expected for the year ending December 31, 2020. As such, the information included in this Quarterly Report on Form 10-Q should be read in conjunction with the Company’s audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019. The balance sheet at December 31, 2019 has been derived from the audited consolidated financial statements of the Company but does not include all the disclosures required by GAAP. Additionally, t he outbreak of the novel coronavirus, or COVID-19, and the various governmental, industry and consumer actions related thereto, could have a material and adverse effect on our business, financial condition and results of operations. These effects, which largely depend on future developments that cannot be accurately predicted and are uncertain, could include a negative impact on the availability of our key personnel, temporary closures of our facilities or the facilities of our business partners, customers, suppliers, third party service providers or other vendors, an increased risk of customer defaults or delays in payments or purchasing decisions, and the interruption of domestic and global supply chains, distribution channels, liquidity and capital or financial markets. As COVID-19 continues to spread, we have and may continue to experience disruptions that could severely impact our business. As such, the results for the three and six months ended June 30, 2020 may not be indicative of results for the full year. Recently Issued Accounting Standards Accounting pronouncements adopted In August 2018, the FASB issued new accounting guidance that clarifies and aligns the accounting for implementation costs for hosting arrangements with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The Company adopted this new accounting guidance on January 1, 2020. The adoption of this new accounting guidance did not have a material effect on the Company’s consolidated financial statements. In August 2018, the FASB issued new accounting guidance that modifies the disclosure requirements in Topic 820, Fair Value Measurement, by removing certain disclosure requirements related to the fair value hierarchy, modifying existing disclosure requirements related to measurement uncertainty and adding new disclosure requirements, such as disclosing the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period and disclosing the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. This new accounting guidance also modifies the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans. The Company adopted this new accounting guidance on January 1, 2020. The adoption of this new accounting guidance did not have a material effect on the Company’s consolidated financial statements. In January 2017, the FASB issued new accounting guidance that simplifies the measurement of goodwill by eliminating the step two impairment test. Step two measures a goodwill impairment loss by comparing the implied fair value of goodwill with the carrying amount of that goodwill. The new guidance requires a comparison of the Company’s fair value of a reporting unit with the carrying amount and the Company is required to recognize an impairment charge for the amount by which the carrying amount exceeds the fair value. The Company adopted this new accounting guidance on January 1, 2020. The adoption of this new accounting guidance did not have a material effect on the Company’s consolidated financial statements. In June 2016, the FASB issued a new accounting standard intended to provide financial statement users with more decision-useful information about expected credit losses and other commitments to extend credit held by the reporting entity. The standard replaces the incurred loss impairment methodology in current GAAP with one that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The Company adopted this new accounting guidance on January 1, 2020. The adoption of this guidance did not have a material effect on the Company’s consolidated financial statements. This is based on factors including the Company's assessment of historical losses, client's creditworthiness and the fact that the Company's trade receivables are short term in duration. Accounting pronouncements being evaluated In January 2020, the FASB issued new accounting guidance that states any equity security transitioning from the alternative method of accounting to the equity method, or vice versa, due to an observable transaction, will be remeasured immediately before the transition. In addition, the new accounting guidance clarifies the accounting for certain non-derivative forward contracts or purchased call options to acquire equity securities stating such instruments will be measured using the fair value principles before settlement or exercise. The new accounting guidance will be effective for the Company on January 1, 2021 on a prospective basis. Early adoption is permitted. The Company is currently evaluating the impact of this new accounting guidance on its consolidated financial statements. In December 2019, the FASB issued new accounting guidance to clarify and simplify the accounting for income taxes. Changes under the new guidance includes eliminating certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new accounting guidance will be effective for the Company on January 1, 2021. Early adoption is permitted. The Company is currently evaluating the impact of this new accounting guidance on its consolidated financial statements. |
Revenues by Geography, Concentr
Revenues by Geography, Concentration of Credit Risk and Remaining Performance Obligations | 6 Months Ended |
Jun. 30, 2020 | |
Revenue from Contract with Customer [Abstract] | |
Revenues by Geography, Concentration of Credit Risk and Remaining Performance Obligations | Revenues by Geography, Concentration of Credit Risk and Remaining Performance Obligations The following tables represent revenues by geographic region and reportable segment for the three and six months ended June 30, 2020 and 2019: Three Months Ended June 30, 2020 (in millions) Technology & Analytics Solutions Research & Development Solutions Contract Sales & Medical Solutions Total Revenues: Americas $ 567 $ 528 $ 80 $ 1,175 Europe and Africa 401 375 40 816 Asia-Pacific 141 332 57 530 Total revenues $ 1,109 $ 1,235 $ 177 $ 2,521 Three Months Ended June 30, 2019 (in millions) Technology & Analytics Solutions Research & Development Solutions Contract Sales & Medical Solutions Total Revenues: Americas $ 588 $ 642 $ 100 $ 1,330 Europe and Africa 376 448 49 873 Asia-Pacific 138 345 54 537 Total revenues $ 1,102 $ 1,435 $ 203 $ 2,740 Six Months Ended June 30, 2020 (in millions) Technology & Analytics Solutions Research & Development Solutions Contract Sales & Medical Solutions Total Revenues: Americas $ 1,148 $ 1,198 $ 171 $ 2,517 Europe and Africa 797 803 90 1,690 Asia-Pacific 281 675 112 1,068 Total revenues $ 2,226 $ 2,676 $ 373 $ 5,275 Six Months Ended June 30, 2019 (in millions) Technology & Research & Contract Sales & Total Revenues: Americas $ 1,142 $ 1,283 $ 194 $ 2,619 Europe and Africa 759 904 100 1,763 Asia-Pacific 276 664 102 1,042 Total revenues $ 2,177 $ 2,851 $ 396 $ 5,424 No customer accounted for 10% or more of consolidated revenues for the three and six months ended June 30, 2020 or 2019. Transaction Price Allocated to the Remaining Performance Obligations |
Trade Accounts Receivable, Unbi
Trade Accounts Receivable, Unbilled Services and Unearned Income | 6 Months Ended |
Jun. 30, 2020 | |
Receivables [Abstract] | |
Trade Accounts Receivable, Unbilled Services and Unearned Income | Trade Accounts Receivable, Unbilled Services and Unearned Income Trade accounts receivables and unbilled services consist of the following: (in millions) June 30, 2020 December 31, 2019 Trade accounts receivable: Billed $ 1,105 $ 1,312 Unbilled services 1,285 1,286 Trade accounts receivable and unbilled services 2,390 2,598 Allowance for doubtful accounts (19) (16) Trade accounts receivable and unbilled services, net $ 2,371 $ 2,582 Unbilled services and unearned income were as follows: (in millions) June 30, 2020 December 31, 2019 Change Unbilled services $ 1,285 $ 1,286 $ (1) Unearned income (1,061) (1,014) (47) Net balance $ 224 $ 272 $ (48) Unbilled services, which is comprised of approximately 60% of unbilled receivables and 40% of contract assets as of June 30, 2020, decreased by $1 million as compared to December 31, 2019. Contract assets are unbilled services for which invoicing is based on the timing of certain milestones related to service contracts for clinical research whereas unbilled receivables are billable upon the passage of time. Unearned income increased by $47 million over the same period resulting in a decrease of $48 million in the net balance of unbilled services and unearned income between December 31, 2019 and June 30, 2020. The change in the net balance is driven by the difference in timing of revenue recognition in accordance with ASC 606, Revenue from Contracts with Customers, related to the Company’s Research & Development Solutions contracts (which is based on the percentage of costs incurred) versus the timing of invoicing, which is based on certain milestones. |
Leases
Leases | 6 Months Ended |
Jun. 30, 2020 | |
Leases [Abstract] | |
Leases | Leases The Company has operating leases for corporate offices, datacenters, motor vehicles and certain equipment, many of which contain renewal and escalation clauses. These operating leases expire at various dates through 2029 with options to cancel certain leases at various intervals. The Company also has finance leases for office and lab spaces that expire in 2044. Based on the timing of payments on the finance leases the cash flow impact is not material for the three and six months ended June 30, 2020. In determining the lease term at lease commencement, the Company includes the noncancellable term and the periods which the Company deems it is reasonably certain to exercise or not to exercise a renewal or cancellation option. The components of lease expense were as follows: (in millions) Classification Three Months Ended June 30, 2020 Three Months Ended June 30, 2019 Operating lease cost (1) Selling, general and administrative expenses $ 53 $ 47 Finance lease cost (1) Depreciation and amortization, and Interest expense 1 — Total lease cost $ 54 $ 47 (in millions) Classification Six Months Ended June 30, 2020 Six Months Ended June 30, 2019 Operating lease cost (1) Selling, general and administrative expenses $ 102 $ 95 Finance lease cost (1) Depreciation and amortization, and Interest expense 1 — Total lease cost $ 103 $ 95 (1) Includes variable lease costs, which are immaterial. Other information related to leases was as follows: (in millions) Six Months Ended June 30, 2020 Six Months Ended June 30, 2019 Supplemental Cash Flow: Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 102 $ 92 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ 75 $ 28 Finance leases $ 119 $ — Weighted Average Remaining Lease Term: Operating leases 4.77 years 5.22 years Finance leases 24.50 years — Weighted Average Discount Rate: Operating leases 4.11 % 4.26 % Finance leases 3.18 % — Future minimum lease payments under non-cancellable leases as of June 30, 2020 were as follows: (in millions) Operating Leases Finance Leases Remainder of 2020 $ 86 $ — 2021 148 — 2022 124 6 2023 95 6 2024 66 6 2025 53 6 Thereafter 43 159 Total future minimum lease payments 615 183 Less imputed interest (59) (63) Total $ 556 $ 120 Reported as of June 30, 2020: Other current liabilities $ 154 $ — Operating lease liabilities 402 — Other liabilities — 120 Total $ 556 $ 120 |
Goodwill
Goodwill | 6 Months Ended |
Jun. 30, 2020 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Goodwill | Goodwill The following is a summary of goodwill by reportable segment for the six months ended June 30, 2020: (in millions) Technology & Analytics Solutions Research & Development Solutions Contract Sales & Medical Solutions Consolidated Balance as of December 31, 2019 $ 10,374 $ 1,646 $ 139 $ 12,159 Business combinations 70 — — 70 Impact of foreign currency fluctuations and other (51) (48) 3 (96) Balance as of June 30, 2020 $ 10,393 $ 1,598 $ 142 $ 12,133 |
Derivatives
Derivatives | 6 Months Ended |
Jun. 30, 2020 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
Derivatives | Derivatives The fair values of the Company’s derivative instruments and the line items on the accompanying condensed consolidated balance sheets to which they were recorded are summarized in the following table: (in millions) Balance Sheet Classification June 30, 2020 December 31, 2019 Assets Liabilities Notional Assets Liabilities Notional Derivatives designated as hedging instruments: Foreign exchange forward contracts Other current assets and liabilities $ 1 $ 3 $ 114 $ 4 $ — $ 148 Interest rate swaps Other assets and liabilities — 60 1,800 — 27 875 Derivatives not designated as hedging instruments: Interest rate swaps Other liabilities — 2 326 — 3 325 Total derivatives $ 1 $ 65 $ 4 $ 30 The effect of the Company’s cash flow hedging instruments on other comprehensive income is summarized in the following table: Three Months Ended June 30, Six Months Ended June 30, (in millions) 2020 2019 2020 2019 Foreign exchange forward contracts $ — $ (5) $ (6) $ (4) Interest rate derivatives (10) (15) (33) (24) Total $ (10) $ (20) $ (39) $ (28) The amount of foreign exchange losses related to the net investment hedge included in the cumulative translation adjustment component of accumulated other comprehensive loss (“AOCI”) for the six months ended June 30, 2020 was $8 million. |
Fair Value Measurements
Fair Value Measurements | 6 Months Ended |
Jun. 30, 2020 | |
Fair Value Disclosures [Abstract] | |
Fair Value Measurements | Fair Value Measurements The Company records certain assets and liabilities at fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A three-level fair value hierarchy that prioritizes the inputs used to measure fair value is described below. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: • Level 1 — Quoted prices in active markets for identical assets or liabilities. • Level 2 — Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data. • Level 3 — Unobservable inputs that are supported by little or no market activity. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs. The carrying values of cash, cash equivalents, accounts receivable and accounts payable approximated their fair values at June 30, 2020 and December 31, 2019 due to their short-term nature. At June 30, 2020 and December 31, 2019, the fair value of total debt approximated $12,135 million and $11,925 million, respectively, as determined under Level 1 and Level 2 measurements for these financial instruments. Recurring Fair Value Measurements The following table summarizes the fair value of the Company’s financial assets and liabilities that are measured and reported at fair value on a recurring basis as of June 30, 2020: (in millions) Level 1 Level 2 Level 3 Total Assets: Marketable securities 101 $ — $ — $ 101 Derivatives — $ 1 — 1 Total $ 101 $ 1 $ — $ 102 Liabilities: Derivatives $ — $ 65 $ — $ 65 Contingent consideration — — 111 111 Total $ — $ 65 $ 111 $ 176 Below is a summary of the valuation techniques used in determining fair value: Marketable securities — The Company values trading and available-for-sale securities using the quoted market value of the securities held. Derivatives — Derivatives consist of foreign exchange contracts and interest rate swaps. The fair value of foreign exchange contracts is based on observable market inputs of spot and forward rates or using other observable inputs. The fair value of the interest rate swaps is the estimated amount that the Company would receive or pay to terminate such agreements, taking into account market interest rates and the remaining time to maturities or using market inputs with mid-market pricing as a practical expedient for bid-ask spread. Contingent consideration — The Company values contingent consideration related to business combinations using a weighted probability calculation of potential payment scenarios discounted at rates reflective of the risks associated with the expected future cash flows. Key assumptions used to estimate the fair value of contingent consideration include various financial metrics (revenue performance targets and operating forecasts) and the probability of achieving the specific targets. The following table summarizes the changes in Level 3 financial assets and liabilities measured on a recurring basis for the six months ended June 30: Contingent Consideration (in millions) 2020 2019 Balance as of January 1 $ 113 $ 123 Business combinations 28 29 Contingent consideration paid (17) (39) Revaluations included in earnings and foreign currency translation adjustments (13) (5) Balance as of June 30 $ 111 $ 108 The Company used the following key assumptions when estimating the fair value of contingent considerations: Unobservable Input Weighted average probability of target achievement Range of potential payment Revenue target 86% 0%-100% EBITDA target 96% 0%-100% Operational target 97% 0%-100% The current portion of contingent consideration is included within accrued expenses and the long-term portion is included within other liabilities on the accompanying condensed consolidated balance sheets. Revaluations of the contingent |
Credit Arrangements
Credit Arrangements | 6 Months Ended |
Jun. 30, 2020 | |
Debt Disclosure [Abstract] | |
Credit Arrangements | Credit Arrangements The following is a summary of the Company’s revolving credit facilities at June 30, 2020: Facility Interest Rates $1,500 million (revolving credit facility) LIBOR in the relevant currency borrowed plus a margin of 1.50% at June 30, 2020 $25 million (receivables financing facility) LIBOR Market Index Rate (0.16% at June 30, 2020) plus 0.90% £10 million (approximately $12 million) (general banking facility) Bank’s base rate of 0.10% at June 30, 2020 plus 1% The following table summarizes the Company’s debt at the dates indicated: (in millions) June 30, 2020 December 31, 2019 Senior Secured Credit Facilities: Term A Loan due 2023—U.S. Dollar LIBOR at average floating rates of 1.81% $ 749 $ 770 Term A Loan due 2023—U.S. Dollar LIBOR at average floating rates of 2.75% 789 — Term A Loan due 2023—Euro LIBOR at average floating rates of 1.50% 377 387 Term B Loan due 2024—U.S. Dollar LIBOR at average floating rates of 2.50% 535 535 Term B Loan due 2024—Euro LIBOR at average floating rates of 2.00% 1,300 1,306 Term B Loan due 2025—U.S. Dollar LIBOR at average floating rates of 1.93% 729 733 Term B Loan due 2025—U.S. Dollar LIBOR at average floating rates of 2.06% 931 936 Term B Loan due 2025—Euro LIBOR at average floating rates of 2.00% 642 644 Revolving Credit Facility due 2023: U.S. Dollar denominated borrowings—U.S. Dollar LIBOR at average floating rates of 1.66% — 154 Japanese Yen denominated borrowings—Japanese Yen LIBOR at average floating rates of 1.50% — 212 5.0% Senior Notes due 2027—U.S. Dollar denominated 1,100 1,100 5.0% Senior Notes due 2026—U.S. Dollar denominated 1,050 1,050 2.875% Senior Notes due 2025—Euro denominated 472 471 3.25% Senior Notes due 2025—Euro denominated 1,600 1,598 3.5% Senior Notes due 2024—Euro denominated — 701 2.25% Senior Notes due 2028—Euro denominated 809 808 2.875% Senior Notes due 2028—Euro denominated 798 — Receivables financing facility due 2022—U.S. Dollar LIBOR at average floating rates of 1.06% 300 300 Principal amount of debt 12,181 11,705 Less: unamortized discount and debt issuance costs (74) (60) Less: current portion (142) (100) Long-term debt $ 11,965 $ 11,545 Contractual maturities of long-term debt are as follows at June 30, 2020: (in millions) Remainder of 2020 71 2021 145 2022 445 2023 1,684 2024 1,812 Thereafter 8,024 12,181 At June 30, 2020, there were bank guarantees totaling approximately £0.9 million (approximately $1.1 million) issued against the availability of the general banking facility. Senior Secured Credit Facilities At June 30, 2020, the Company’s Fourth Amended and Restated Credit Agreement, as amended (the “Credit Agreement”) provided financing through several senior secured credit facilities (collectively, the “senior secured credit facilities”) of up to approximately $7.6 billion, which consisted of $6.1 billion principal amounts of debt outstanding (as detailed in the table above), $1.5 billion of available borrowing capacity on the revolving credit facility and standby letters of credit. On March 11, 2020, the Company entered into Amendment No. 7 to the Credit Agreement to borrow $900 million in additional U.S. Dollar denominated term A loans due 2023 (the “TLA-2 Loans”) and, on March 30, 2020, entered into Amendment No. 8 to the Credit Agreement to amend certain terms of the TLA-2 Loans. The TLA-2 Loans bear interest based on the U.S. Dollar LIBOR plus a margin ranging from 1.50% to 2.25%, with a U.S. Dollar LIBOR floor of 1.00% per annum. The proceeds from the TLA-2 Loans were used to repay outstanding revolving credit loans under the Company's senior secured credit facilities. On March 30, 2020, the Company prepaid $100 million of the TLA-2 loans. Senior Notes On June 24, 2020, IQVIA Inc. (the “Issuer”), a wholly owned subsidiary of the Company, completed the issuance and sale of €711,000,000 in gross proceeds of the Issuer’s 2.875% senior notes due 2028 (the “2.875% Notes”). The 2.875% Notes were issued pursuant to an Indenture, dated June 24, 2020, among the Issuer, U.S. Bank National Association, as trustee of the Notes, and certain subsidiaries of the Issuer as guarantors. The 2.875% Notes are unsecured obligations of the Issuer, will mature on June 15, 2028 and bear interest at the rate of 2.875% per year, with interest payable semiannually on June 15 and December 15 of each year, beginning on December 15, 2020. The Issuer may redeem the 2.875% Notes prior to their final stated maturity, subject to a customary make-whole premium, at any time prior to June 15, 2023 (subject to a customary “equity claw” redemption right) and thereafter subject to a redemption premium declining from 1.438% to 0.000%. The proceeds from the 2.875% Notes offering were used to redeem all of the Issuer’s outstanding 3.500% senior notes due 2024 (the “3.500% Notes”), including the payment of premiums in respect thereof, to repay a portion of the existing borrowings under the Issuer’s revolving credit facility and to pay fees and expenses related to the offering. The Issuer’s obligations with respect to the 3.500% Notes were discharged on the same day as the Issuer completed the issuance of the 2.875% Notes, and the 3.500% Notes were redeemed on July 9, 2020. Restrictive Covenants The Company’s debt agreements provide for certain covenants and events of default customary for similar instruments, including a covenant not to exceed a specified ratio of consolidated senior secured net indebtedness to Consolidated EBITDA, as defined in the senior secured credit facility agreement and a covenant to maintain a specified minimum interest coverage ratio. If an event of default occurs under any of the Company’s or the Company’s subsidiaries’ financing arrangements, the creditors under such financing arrangements will be entitled to take various actions, including the acceleration of amounts due under such arrangements, and in the case of the lenders under the revolving credit facility and term loans, other actions permitted to be taken by a secured creditor. The Company’s long-term debt arrangements contain other usual and customary restrictive covenants that, among other things, place limitations on the Company’s ability to declare dividends. At June 30, 2020, the Company was in compliance with the financial covenants under its debt agreements in all material respects and does not have material uncertainty about ongoing ability to meet the covenants of the Company's credit arrangements. |
Stockholders' Equity
Stockholders' Equity | 6 Months Ended |
Jun. 30, 2020 | |
Equity [Abstract] | |
Stockholders' Equity | Stockholders’ Equity Preferred Stock The Company is authorized to issue 1.0 million shares of preferred stock, $0.01 per share par value. No shares of preferred stock were issued or outstanding as of June 30, 2020 or December 31, 2019. Equity Repurchase Program Since the COVID-19 outbreak became a pandemic in March, the company temporarily suspended share repurchase activity. During the six months ended June 30, 2020, the Company repurchased 2,106,403 shares of its common stock for approximately $321.4 million under the Repurchase Program. These amounts include 1,000,000 shares of our common stock repurchased from certain of the Company’s stockholders (the “Selling Stockholders”) in a private transaction for an aggregate purchase price of approximately $164.3 million. As of June 30, 2020, the Company has remaining authorization to repurchase up to approximately $1.0 billion of its common stock under the Repurchase Program. In addition, from time to time, the Company has repurchased and may continue to repurchase common stock through private or other transactions outside of the Repurchase Program. |
Restructuring
Restructuring | 6 Months Ended |
Jun. 30, 2020 | |
Restructuring and Related Activities [Abstract] | |
Restructuring | Restructuring The Company has continued to take restructuring actions in 2020 to align its resources and reduce overcapacity to adapt to changing market conditions and integrate acquisitions. These actions include consolidating functional activities, eliminating redundant positions, and aligning resources with customer requirements. These restructuring actions are expected to continue into 2021. The following amounts were recorded for the restructuring plans: (in millions) Severance and Related Costs Facility Exit Costs Total Balance at December 31, 2019 $ 64 $ 3 $ 67 Expense, net of reversals 30 — 30 Payments (37) (1) (38) Foreign currency translation and other (2) — (2) Balance at June 30, 2020 $ 55 $ 2 $ 57 Restructuring costs are not allocated to the Company’s reportable segments as they are not part of the segment performance measures regularly reviewed by management. The Company expects that the majority of the restructuring accruals at June 30, 2020 will be paid in 2020 and 2021. |
Income Taxes
Income Taxes | 6 Months Ended |
Jun. 30, 2020 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | Income Taxes The effective income tax rate was 20.0% and 10.3% in the second quarter of 2020 and 2019, respectively, and 15.6% and 26.2% in the first six months of 2020 and 2019, respectively. The effective income tax rate in the second quarter and first six months of 2020 and 2019 was favorably impacted as a result of excess tax benefits recognized upon settlement of share-based compensation awards. For the second quarter of 2020 and 2019 this impact was $5 million and $8 million, respectively, and for the first six months of 2020 and 2019 this impact was $26 million and $17 million, respectively. Also, the effective income tax rate in the first six months of 2020 was unfavorably impacted by a $10 million discrete tax expense related to change in the measurement of the U.S. tax on undistributed foreign earnings. In the first six months of 2019 the U.S. Treasury Department issued final regulations on the transition tax and proposed regulations on Foreign Derived Intangible Income (“FDII”). While the final regulations related to the transition tax did not have a material impact on the Company, the proposed guidance on FDII had an unfavorable impact. Although the proposed |
Comprehensive Income (Loss)
Comprehensive Income (Loss) | 6 Months Ended |
Jun. 30, 2020 | |
Equity [Abstract] | |
Comprehensive Income (Loss) | Comprehensive Income (Loss) Below is a summary of the components of AOCI: (in millions) Foreign Currency Translation Derivative Instruments Defined Benefit Plans Income Taxes Total Balance at December 31, 2019 $ (430) $ (21) $ (16) $ 156 $ (311) Other comprehensive income (loss) before reclassifications (111) (43) — 17 (137) Reclassification adjustments — 5 — (1) 4 Balance at June 30, 2020 $ (541) $ (59) $ (16) $ 172 $ (444) Below is a summary of the adjustments for (gains) losses reclassified from AOCI into the condensed consolidated statements of income and the affected financial statement line item: (in millions) Affected Financial Statement Line Item Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Derivative instruments: Foreign exchange forward contracts Revenues $ 3 $ — $ 5 $ 1 Foreign exchange forward contracts Other expense (income), net (14) (3) — (6) Total before income taxes (11) (3) 5 (5) Income tax (benefit) expense 1 — 1 (1) Total net of income taxes $ (12) $ (3) $ 4 $ (4) |
Segments
Segments | 6 Months Ended |
Jun. 30, 2020 | |
Segment Reporting [Abstract] | |
Segments | Segments The following table presents the Company’s operations by reportable segment. The Company is managed through three reportable segments, Technology & Analytics Solutions, Research & Development Solutions and Contract Sales & Medical Solutions. Technology & Analytics Solutions provides mission-critical information, technology solutions and real-world insights and services to the Company’s life sciences customers. Research & Development Solutions, which primarily serves biopharmaceutical customers, provides outsourced clinical research and clinical trial related services. Contract Sales & Medical Solutions provides health care provider (including contract sales) and patient engagement services to both biopharmaceutical customers and the broader healthcare market. Certain costs are not allocated to the Company’s segments and are reported as general corporate and unallocated expenses. These costs primarily consist of stock-based compensation and expenses related to integration activities and acquisitions. The Company also does not allocate depreciation and amortization or impairment charges to its segments. Asset information by segment is not presented, as this measure is not used by the chief operating decision maker to assess the Company’s performance. The Company’s reportable segment information is presented below: Three Months Ended June 30, Six Months Ended June 30, (in millions) 2020 2019 2020 2019 Revenues Technology & Analytics Solutions $ 1,109 $ 1,102 $ 2,226 $ 2,177 Research & Development Solutions 1,235 1,435 2,676 2,851 Contract Sales & Medical Solutions 177 203 373 396 Total revenues 2,521 2,740 5,275 5,424 Costs of revenue, exclusive of depreciation and amortization Technology & Analytics Solutions 655 656 1,321 1,289 Research & Development Solutions 898 971 1,886 1,917 Contract Sales & Medical Solutions 151 172 321 341 Total costs of revenue 1,704 1,799 3,528 3,547 Selling, general and administrative expenses Technology & Analytics Solutions 178 188 361 372 Research & Development Solutions 175 176 360 357 Contract Sales & Medical Solutions 15 15 30 30 General corporate and unallocated 63 57 87 96 Total selling, general and administrative expenses 431 436 838 855 Segment profit Technology & Analytics Solutions 276 258 544 516 Research & Development Solutions 162 288 430 577 Contract Sales & Medical Solutions 11 16 22 25 Total segment profit 449 562 996 1,118 General corporate and unallocated (63) (57) (87) (96) Depreciation and amortization (308) (294) (624) (589) Restructuring costs (16) (14) (30) (26) Total income from operations $ 62 $ 197 $ 255 $ 407 |
Earnings Per Share
Earnings Per Share | 6 Months Ended |
Jun. 30, 2020 | |
Earnings Per Share [Abstract] | |
Earnings Per Share | Earnings Per Share The following table presents the weighted average number of outstanding stock-based awards not included in the computation of diluted earnings per share because they are subject to performance conditions or the effect of including such stock-based awards in the computation would be anti-dilutive: Three Months Ended June 30, Six Months Ended June 30, (in millions) 2020 2019 2020 2019 Shares subject to performance conditions 1.1 1.3 1.2 1.3 Shares subject to anti-dilutive stock-based awards 1.8 1.1 1.4 0.8 Dilutive shares excluded from dilutive earnings per share 3.3 — — — Total shares excluded from diluted earnings per share 6.2 2.4 2.6 2.1 The vesting of performance awards is contingent upon the achievement of certain performance targets. The performance awards are not included in diluted earnings per share until the performance targets have been met. Stock-based awards will have a dilutive effect under the treasury method when the respective period’s average market value of the Company’s common stock exceeds the exercise proceeds. For the quarter ended June 30, 2020, all potentially dilutive securities were excluded from the diluted earnings per share calculation because the Company incurred a net loss for this period and their inclusion would be anti-dilutive. |
Summary of Significant Accoun_2
Summary of Significant Accounting Policies (Policies) | 6 Months Ended |
Jun. 30, 2020 | |
Accounting Policies [Abstract] | |
Unaudited Interim Financial Information | Unaudited Interim Financial Information The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair statement of the Company’s financial condition and results of operations have been included. Operating results for the periods presented are not necessarily indicative of the results that may be expected for the year ending December 31, 2020. As such, the information included in this Quarterly Report on Form 10-Q should be read in conjunction with the Company’s audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019. The balance sheet at December 31, 2019 has been derived from the audited consolidated financial statements of the Company but does not include all the disclosures required by GAAP. Additionally, t he outbreak of the novel coronavirus, or COVID-19, and the various governmental, industry and consumer actions related thereto, could have a material and adverse effect on our business, financial condition and results of operations. These effects, which largely depend on future developments that cannot be accurately predicted and are uncertain, could include a negative impact on the availability of our key personnel, temporary closures of our facilities or the facilities of our business partners, customers, suppliers, third party service providers or other vendors, an increased risk of customer defaults or delays in payments or purchasing decisions, and the interruption of domestic and global supply chains, distribution channels, liquidity and capital or financial markets. As COVID-19 continues to spread, we have and may continue to experience disruptions that could severely impact our business. As such, the results for the three and six months ended June 30, 2020 may not be indicative of results for the full year. |
Recently Issued Accounting Standards | Recently Issued Accounting Standards Accounting pronouncements adopted In August 2018, the FASB issued new accounting guidance that clarifies and aligns the accounting for implementation costs for hosting arrangements with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The Company adopted this new accounting guidance on January 1, 2020. The adoption of this new accounting guidance did not have a material effect on the Company’s consolidated financial statements. In August 2018, the FASB issued new accounting guidance that modifies the disclosure requirements in Topic 820, Fair Value Measurement, by removing certain disclosure requirements related to the fair value hierarchy, modifying existing disclosure requirements related to measurement uncertainty and adding new disclosure requirements, such as disclosing the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period and disclosing the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. This new accounting guidance also modifies the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans. The Company adopted this new accounting guidance on January 1, 2020. The adoption of this new accounting guidance did not have a material effect on the Company’s consolidated financial statements. In January 2017, the FASB issued new accounting guidance that simplifies the measurement of goodwill by eliminating the step two impairment test. Step two measures a goodwill impairment loss by comparing the implied fair value of goodwill with the carrying amount of that goodwill. The new guidance requires a comparison of the Company’s fair value of a reporting unit with the carrying amount and the Company is required to recognize an impairment charge for the amount by which the carrying amount exceeds the fair value. The Company adopted this new accounting guidance on January 1, 2020. The adoption of this new accounting guidance did not have a material effect on the Company’s consolidated financial statements. In June 2016, the FASB issued a new accounting standard intended to provide financial statement users with more decision-useful information about expected credit losses and other commitments to extend credit held by the reporting entity. The standard replaces the incurred loss impairment methodology in current GAAP with one that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The Company adopted this new accounting guidance on January 1, 2020. The adoption of this guidance did not have a material effect on the Company’s consolidated financial statements. This is based on factors including the Company's assessment of historical losses, client's creditworthiness and the fact that the Company's trade receivables are short term in duration. Accounting pronouncements being evaluated In January 2020, the FASB issued new accounting guidance that states any equity security transitioning from the alternative method of accounting to the equity method, or vice versa, due to an observable transaction, will be remeasured immediately before the transition. In addition, the new accounting guidance clarifies the accounting for certain non-derivative forward contracts or purchased call options to acquire equity securities stating such instruments will be measured using the fair value principles before settlement or exercise. The new accounting guidance will be effective for the Company on January 1, 2021 on a prospective basis. Early adoption is permitted. The Company is currently evaluating the impact of this new accounting guidance on its consolidated financial statements. In December 2019, the FASB issued new accounting guidance to clarify and simplify the accounting for income taxes. Changes under the new guidance includes eliminating certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new accounting guidance will be effective for the Company on January 1, 2021. Early adoption is permitted. The Company is currently evaluating the impact of this new accounting guidance on its consolidated financial statements. |
Revenues by Geography, Concen_2
Revenues by Geography, Concentration of Credit Risk and Remaining Performance Obligations (Tables) | 6 Months Ended |
Jun. 30, 2020 | |
Revenue from Contract with Customer [Abstract] | |
Summary of Revenues by Geographic Region and Reportable Segment | The following tables represent revenues by geographic region and reportable segment for the three and six months ended June 30, 2020 and 2019: Three Months Ended June 30, 2020 (in millions) Technology & Analytics Solutions Research & Development Solutions Contract Sales & Medical Solutions Total Revenues: Americas $ 567 $ 528 $ 80 $ 1,175 Europe and Africa 401 375 40 816 Asia-Pacific 141 332 57 530 Total revenues $ 1,109 $ 1,235 $ 177 $ 2,521 Three Months Ended June 30, 2019 (in millions) Technology & Analytics Solutions Research & Development Solutions Contract Sales & Medical Solutions Total Revenues: Americas $ 588 $ 642 $ 100 $ 1,330 Europe and Africa 376 448 49 873 Asia-Pacific 138 345 54 537 Total revenues $ 1,102 $ 1,435 $ 203 $ 2,740 Six Months Ended June 30, 2020 (in millions) Technology & Analytics Solutions Research & Development Solutions Contract Sales & Medical Solutions Total Revenues: Americas $ 1,148 $ 1,198 $ 171 $ 2,517 Europe and Africa 797 803 90 1,690 Asia-Pacific 281 675 112 1,068 Total revenues $ 2,226 $ 2,676 $ 373 $ 5,275 Six Months Ended June 30, 2019 (in millions) Technology & Research & Contract Sales & Total Revenues: Americas $ 1,142 $ 1,283 $ 194 $ 2,619 Europe and Africa 759 904 100 1,763 Asia-Pacific 276 664 102 1,042 Total revenues $ 2,177 $ 2,851 $ 396 $ 5,424 |
Trade Accounts Receivable, Un_2
Trade Accounts Receivable, Unbilled Services and Unearned Income (Tables) | 6 Months Ended |
Jun. 30, 2020 | |
Receivables [Abstract] | |
Schedule of Trade Accounts Receivable and Unbilled Services | Trade accounts receivables and unbilled services consist of the following: (in millions) June 30, 2020 December 31, 2019 Trade accounts receivable: Billed $ 1,105 $ 1,312 Unbilled services 1,285 1,286 Trade accounts receivable and unbilled services 2,390 2,598 Allowance for doubtful accounts (19) (16) Trade accounts receivable and unbilled services, net $ 2,371 $ 2,582 |
Schedule of Net Contract Assets (Liabilities) | Unbilled services and unearned income were as follows: (in millions) June 30, 2020 December 31, 2019 Change Unbilled services $ 1,285 $ 1,286 $ (1) Unearned income (1,061) (1,014) (47) Net balance $ 224 $ 272 $ (48) |
Leases (Tables)
Leases (Tables) | 6 Months Ended |
Jun. 30, 2020 | |
Leases [Abstract] | |
Schedule of Components of Lease Expense | The components of lease expense were as follows: (in millions) Classification Three Months Ended June 30, 2020 Three Months Ended June 30, 2019 Operating lease cost (1) Selling, general and administrative expenses $ 53 $ 47 Finance lease cost (1) Depreciation and amortization, and Interest expense 1 — Total lease cost $ 54 $ 47 (in millions) Classification Six Months Ended June 30, 2020 Six Months Ended June 30, 2019 Operating lease cost (1) Selling, general and administrative expenses $ 102 $ 95 Finance lease cost (1) Depreciation and amortization, and Interest expense 1 — Total lease cost $ 103 $ 95 (1) Includes variable lease costs, which are immaterial. |
Summary of Other Information Related to Leases | Other information related to leases was as follows: (in millions) Six Months Ended June 30, 2020 Six Months Ended June 30, 2019 Supplemental Cash Flow: Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 102 $ 92 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ 75 $ 28 Finance leases $ 119 $ — Weighted Average Remaining Lease Term: Operating leases 4.77 years 5.22 years Finance leases 24.50 years — Weighted Average Discount Rate: Operating leases 4.11 % 4.26 % Finance leases 3.18 % — |
Schedule of Future Minimum Lease Payments Under Non-cancellable Leases | Future minimum lease payments under non-cancellable leases as of June 30, 2020 were as follows: (in millions) Operating Leases Finance Leases Remainder of 2020 $ 86 $ — 2021 148 — 2022 124 6 2023 95 6 2024 66 6 2025 53 6 Thereafter 43 159 Total future minimum lease payments 615 183 Less imputed interest (59) (63) Total $ 556 $ 120 Reported as of June 30, 2020: Other current liabilities $ 154 $ — Operating lease liabilities 402 — Other liabilities — 120 Total $ 556 $ 120 |
Goodwill (Tables)
Goodwill (Tables) | 6 Months Ended |
Jun. 30, 2020 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Summary of Goodwill by Reportable Segment | The following is a summary of goodwill by reportable segment for the six months ended June 30, 2020: (in millions) Technology & Analytics Solutions Research & Development Solutions Contract Sales & Medical Solutions Consolidated Balance as of December 31, 2019 $ 10,374 $ 1,646 $ 139 $ 12,159 Business combinations 70 — — 70 Impact of foreign currency fluctuations and other (51) (48) 3 (96) Balance as of June 30, 2020 $ 10,393 $ 1,598 $ 142 $ 12,133 |
Derivatives (Tables)
Derivatives (Tables) | 6 Months Ended |
Jun. 30, 2020 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
Summary of Fair Values of Derivative Instruments Designated as Hedges | The fair values of the Company’s derivative instruments and the line items on the accompanying condensed consolidated balance sheets to which they were recorded are summarized in the following table: (in millions) Balance Sheet Classification June 30, 2020 December 31, 2019 Assets Liabilities Notional Assets Liabilities Notional Derivatives designated as hedging instruments: Foreign exchange forward contracts Other current assets and liabilities $ 1 $ 3 $ 114 $ 4 $ — $ 148 Interest rate swaps Other assets and liabilities — 60 1,800 — 27 875 Derivatives not designated as hedging instruments: Interest rate swaps Other liabilities — 2 326 — 3 325 Total derivatives $ 1 $ 65 $ 4 $ 30 |
Schedule of Effect of Cash Flow Hedging Instruments on Other Comprehensive (Loss) Income | The effect of the Company’s cash flow hedging instruments on other comprehensive income is summarized in the following table: Three Months Ended June 30, Six Months Ended June 30, (in millions) 2020 2019 2020 2019 Foreign exchange forward contracts $ — $ (5) $ (6) $ (4) Interest rate derivatives (10) (15) (33) (24) Total $ (10) $ (20) $ (39) $ (28) |
Fair Value Measurements (Tables
Fair Value Measurements (Tables) | 6 Months Ended |
Jun. 30, 2020 | |
Fair Value Disclosures [Abstract] | |
Summary of Fair Value of Financial Assets and Liabilities Measured on Recurring Basis | The following table summarizes the fair value of the Company’s financial assets and liabilities that are measured and reported at fair value on a recurring basis as of June 30, 2020: (in millions) Level 1 Level 2 Level 3 Total Assets: Marketable securities 101 $ — $ — $ 101 Derivatives — $ 1 — 1 Total $ 101 $ 1 $ — $ 102 Liabilities: Derivatives $ — $ 65 $ — $ 65 Contingent consideration — — 111 111 Total $ — $ 65 $ 111 $ 176 |
Schedule of Changes in Level 3 Financial Assets and Liabilities Measured on Recurring Basis | The following table summarizes the changes in Level 3 financial assets and liabilities measured on a recurring basis for the six months ended June 30: Contingent Consideration (in millions) 2020 2019 Balance as of January 1 $ 113 $ 123 Business combinations 28 29 Contingent consideration paid (17) (39) Revaluations included in earnings and foreign currency translation adjustments (13) (5) Balance as of June 30 $ 111 $ 108 |
Schedule of Fair Value Measurement Inputs and Valuation Techniques | The Company used the following key assumptions when estimating the fair value of contingent considerations: Unobservable Input Weighted average probability of target achievement Range of potential payment Revenue target 86% 0%-100% EBITDA target 96% 0%-100% Operational target 97% 0%-100% |
Credit Arrangements (Tables)
Credit Arrangements (Tables) | 6 Months Ended |
Jun. 30, 2020 | |
Debt Disclosure [Abstract] | |
Summary of Credit Facilities | The following is a summary of the Company’s revolving credit facilities at June 30, 2020: Facility Interest Rates $1,500 million (revolving credit facility) LIBOR in the relevant currency borrowed plus a margin of 1.50% at June 30, 2020 $25 million (receivables financing facility) LIBOR Market Index Rate (0.16% at June 30, 2020) plus 0.90% £10 million (approximately $12 million) (general banking facility) Bank’s base rate of 0.10% at June 30, 2020 plus 1% |
Summary of Debt | The following table summarizes the Company’s debt at the dates indicated: (in millions) June 30, 2020 December 31, 2019 Senior Secured Credit Facilities: Term A Loan due 2023—U.S. Dollar LIBOR at average floating rates of 1.81% $ 749 $ 770 Term A Loan due 2023—U.S. Dollar LIBOR at average floating rates of 2.75% 789 — Term A Loan due 2023—Euro LIBOR at average floating rates of 1.50% 377 387 Term B Loan due 2024—U.S. Dollar LIBOR at average floating rates of 2.50% 535 535 Term B Loan due 2024—Euro LIBOR at average floating rates of 2.00% 1,300 1,306 Term B Loan due 2025—U.S. Dollar LIBOR at average floating rates of 1.93% 729 733 Term B Loan due 2025—U.S. Dollar LIBOR at average floating rates of 2.06% 931 936 Term B Loan due 2025—Euro LIBOR at average floating rates of 2.00% 642 644 Revolving Credit Facility due 2023: U.S. Dollar denominated borrowings—U.S. Dollar LIBOR at average floating rates of 1.66% — 154 Japanese Yen denominated borrowings—Japanese Yen LIBOR at average floating rates of 1.50% — 212 5.0% Senior Notes due 2027—U.S. Dollar denominated 1,100 1,100 5.0% Senior Notes due 2026—U.S. Dollar denominated 1,050 1,050 2.875% Senior Notes due 2025—Euro denominated 472 471 3.25% Senior Notes due 2025—Euro denominated 1,600 1,598 3.5% Senior Notes due 2024—Euro denominated — 701 2.25% Senior Notes due 2028—Euro denominated 809 808 2.875% Senior Notes due 2028—Euro denominated 798 — Receivables financing facility due 2022—U.S. Dollar LIBOR at average floating rates of 1.06% 300 300 Principal amount of debt 12,181 11,705 Less: unamortized discount and debt issuance costs (74) (60) Less: current portion (142) (100) Long-term debt $ 11,965 $ 11,545 |
Schedule of Contractual Maturities of Long-term Debt | Contractual maturities of long-term debt are as follows at June 30, 2020: (in millions) Remainder of 2020 71 2021 145 2022 445 2023 1,684 2024 1,812 Thereafter 8,024 12,181 |
Restructuring (Tables)
Restructuring (Tables) | 6 Months Ended |
Jun. 30, 2020 | |
Restructuring and Related Activities [Abstract] | |
Summary of Amounts Recorded for Restructuring Plans | The following amounts were recorded for the restructuring plans: (in millions) Severance and Related Costs Facility Exit Costs Total Balance at December 31, 2019 $ 64 $ 3 $ 67 Expense, net of reversals 30 — 30 Payments (37) (1) (38) Foreign currency translation and other (2) — (2) Balance at June 30, 2020 $ 55 $ 2 $ 57 |
Comprehensive Income (Loss) (Ta
Comprehensive Income (Loss) (Tables) | 6 Months Ended |
Jun. 30, 2020 | |
Equity [Abstract] | |
Summary of Components of AOCI | Below is a summary of the components of AOCI: (in millions) Foreign Currency Translation Derivative Instruments Defined Benefit Plans Income Taxes Total Balance at December 31, 2019 $ (430) $ (21) $ (16) $ 156 $ (311) Other comprehensive income (loss) before reclassifications (111) (43) — 17 (137) Reclassification adjustments — 5 — (1) 4 Balance at June 30, 2020 $ (541) $ (59) $ (16) $ 172 $ (444) |
Summary of Adjustments for (Gains) Losses Reclassified from AOCI into Condensed Consolidated Statements of Income and Affected Financial Statement Line Item | Below is a summary of the adjustments for (gains) losses reclassified from AOCI into the condensed consolidated statements of income and the affected financial statement line item: (in millions) Affected Financial Statement Line Item Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Derivative instruments: Foreign exchange forward contracts Revenues $ 3 $ — $ 5 $ 1 Foreign exchange forward contracts Other expense (income), net (14) (3) — (6) Total before income taxes (11) (3) 5 (5) Income tax (benefit) expense 1 — 1 (1) Total net of income taxes $ (12) $ (3) $ 4 $ (4) |
Segments (Tables)
Segments (Tables) | 6 Months Ended |
Jun. 30, 2020 | |
Segment Reporting [Abstract] | |
Reconciliation of Revenues and Income from Segments to Consolidated | Asset information by segment is not presented, as this measure is not used by the chief operating decision maker to assess the Company’s performance. The Company’s reportable segment information is presented below: Three Months Ended June 30, Six Months Ended June 30, (in millions) 2020 2019 2020 2019 Revenues Technology & Analytics Solutions $ 1,109 $ 1,102 $ 2,226 $ 2,177 Research & Development Solutions 1,235 1,435 2,676 2,851 Contract Sales & Medical Solutions 177 203 373 396 Total revenues 2,521 2,740 5,275 5,424 Costs of revenue, exclusive of depreciation and amortization Technology & Analytics Solutions 655 656 1,321 1,289 Research & Development Solutions 898 971 1,886 1,917 Contract Sales & Medical Solutions 151 172 321 341 Total costs of revenue 1,704 1,799 3,528 3,547 Selling, general and administrative expenses Technology & Analytics Solutions 178 188 361 372 Research & Development Solutions 175 176 360 357 Contract Sales & Medical Solutions 15 15 30 30 General corporate and unallocated 63 57 87 96 Total selling, general and administrative expenses 431 436 838 855 Segment profit Technology & Analytics Solutions 276 258 544 516 Research & Development Solutions 162 288 430 577 Contract Sales & Medical Solutions 11 16 22 25 Total segment profit 449 562 996 1,118 General corporate and unallocated (63) (57) (87) (96) Depreciation and amortization (308) (294) (624) (589) Restructuring costs (16) (14) (30) (26) Total income from operations $ 62 $ 197 $ 255 $ 407 |
Earnings Per Share (Tables)
Earnings Per Share (Tables) | 6 Months Ended |
Jun. 30, 2020 | |
Earnings Per Share [Abstract] | |
Summary of Weighted-Average Outstanding Stock-Based Awards Excluded from Computation of Diluted Earnings Per Share | The following table presents the weighted average number of outstanding stock-based awards not included in the computation of diluted earnings per share because they are subject to performance conditions or the effect of including such stock-based awards in the computation would be anti-dilutive: Three Months Ended June 30, Six Months Ended June 30, (in millions) 2020 2019 2020 2019 Shares subject to performance conditions 1.1 1.3 1.2 1.3 Shares subject to anti-dilutive stock-based awards 1.8 1.1 1.4 0.8 Dilutive shares excluded from dilutive earnings per share 3.3 — — — Total shares excluded from diluted earnings per share 6.2 2.4 2.6 2.1 |
Summary of Significant Accoun_3
Summary of Significant Accounting Policies - Additional Information (Detail) Employee in Thousands | Jun. 30, 2020EmployeeCountry |
Summary Of Significant Accounting Policies [Line Items] | |
Number of employees | Employee | 67 |
Minimum | |
Summary Of Significant Accounting Policies [Line Items] | |
Number of countries (more than) | Country | 100 |
Revenues by Geography, Concen_3
Revenues by Geography, Concentration of Credit Risk and Remaining Performance Obligations - Summary of Revenues by Geographic Region and Reportable Segment (Detail) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2020 | Jun. 30, 2019 | |
Disaggregation of Revenue | ||||
Total revenues | $ 2,521 | $ 2,740 | $ 5,275 | $ 5,424 |
Americas | ||||
Disaggregation of Revenue | ||||
Total revenues | 1,175 | 1,330 | 2,517 | 2,619 |
Europe and Africa | ||||
Disaggregation of Revenue | ||||
Total revenues | 816 | 873 | 1,690 | 1,763 |
Asia-Pacific | ||||
Disaggregation of Revenue | ||||
Total revenues | 530 | 537 | 1,068 | 1,042 |
Technology & Analytics Solutions | ||||
Disaggregation of Revenue | ||||
Total revenues | 1,109 | 1,102 | 2,226 | 2,177 |
Technology & Analytics Solutions | Americas | ||||
Disaggregation of Revenue | ||||
Total revenues | 567 | 588 | 1,148 | 1,142 |
Technology & Analytics Solutions | Europe and Africa | ||||
Disaggregation of Revenue | ||||
Total revenues | 401 | 376 | 797 | 759 |
Technology & Analytics Solutions | Asia-Pacific | ||||
Disaggregation of Revenue | ||||
Total revenues | 141 | 138 | 281 | 276 |
Research & Development Solutions | ||||
Disaggregation of Revenue | ||||
Total revenues | 1,235 | 1,435 | 2,676 | 2,851 |
Research & Development Solutions | Americas | ||||
Disaggregation of Revenue | ||||
Total revenues | 528 | 642 | 1,198 | 1,283 |
Research & Development Solutions | Europe and Africa | ||||
Disaggregation of Revenue | ||||
Total revenues | 375 | 448 | 803 | 904 |
Research & Development Solutions | Asia-Pacific | ||||
Disaggregation of Revenue | ||||
Total revenues | 332 | 345 | 675 | 664 |
Contract Sales & Medical Solutions | ||||
Disaggregation of Revenue | ||||
Total revenues | 177 | 203 | 373 | 396 |
Contract Sales & Medical Solutions | Americas | ||||
Disaggregation of Revenue | ||||
Total revenues | 80 | 100 | 171 | 194 |
Contract Sales & Medical Solutions | Europe and Africa | ||||
Disaggregation of Revenue | ||||
Total revenues | 40 | 49 | 90 | 100 |
Contract Sales & Medical Solutions | Asia-Pacific | ||||
Disaggregation of Revenue | ||||
Total revenues | $ 57 | $ 54 | $ 112 | $ 102 |
Revenues by Geography, Concen_4
Revenues by Geography, Concentration of Credit Risk and Remaining Performance Obligations - Additional Information (Detail) $ in Billions | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2020USD ($)Customer | Jun. 30, 2019Customer | Jun. 30, 2020USD ($)Customer | Jun. 30, 2019Customer | |
Revenue from Contract with Customer [Abstract] | ||||
Number of customer accounting for ten percent or more of revenue | Customer | 0 | 0 | 0 | 0 |
Revenue expected to be recognized in future from remaining performance obligations | $ | $ 22.6 | $ 22.6 |
Revenues by Geography, Concen_5
Revenues by Geography, Concentration of Credit Risk and Remaining Performance Obligations - Future Obligation Terms (Detail) - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-07-01 | Jun. 30, 2020 |
Disaggregation of Revenue | |
Percentage of remaining performance obligations on which revenue is expected to be recognized (in percent) | 35.00% |
Unearned income recognition period | 12 months |
Trade Accounts Receivable, Un_3
Trade Accounts Receivable, Unbilled Services and Unearned Income - Trade Accounts Receivable and Unbilled Services (Detail) - USD ($) $ in Millions | Jun. 30, 2020 | Dec. 31, 2019 |
Trade accounts receivable: | ||
Billed | $ 1,105 | $ 1,312 |
Unbilled services | 1,285 | 1,286 |
Trade accounts receivable and unbilled services | 2,390 | 2,598 |
Allowance for doubtful accounts | (19) | (16) |
Trade accounts receivable and unbilled services, net | $ 2,371 | $ 2,582 |
Trade Accounts Receivable, Un_4
Trade Accounts Receivable, Unbilled Services and Unearned Income - Schedule of Net Contract Assets (Liabilities) (Detail) - USD ($) $ in Millions | 6 Months Ended | |
Jun. 30, 2020 | Dec. 31, 2019 | |
Contract with Customer, Asset and Liability [Abstract] | ||
Unbilled services | $ 1,285 | $ 1,286 |
Unearned income | (1,061) | (1,014) |
Net balance | 224 | $ 272 |
Unbilled Services, Change | (1) | |
Unearned Income, Change | (47) | |
Net balance, Change | $ (48) |
Trade Accounts Receivable, Un_5
Trade Accounts Receivable, Unbilled Services and Unearned Income - Additional Information (Detail) $ in Millions | 6 Months Ended |
Jun. 30, 2020USD ($) | |
Receivables [Abstract] | |
Decrease in unbilled services | $ 1 |
Unbilled receivables (percentage) | 60.00% |
Contract assets (percentage) | 40.00% |
Change in unearned income | $ 47 |
Net change in balance | $ 48 |
Leases - Additional Information
Leases - Additional Information (Detail) | 6 Months Ended |
Jun. 30, 2020 | |
Leases [Abstract] | |
Operating lease year of expiry | 2029 |
Leases - Components of Lease Ex
Leases - Components of Lease Expense (Detail) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2020 | Jun. 30, 2019 | |
Lease, Cost | $ 54 | $ 47 | $ 103 | $ 95 |
Selling, general and administrative expenses | ||||
Operating lease cost | 53 | 47 | 102 | 95 |
Depreciation And Amortization And Interest [Member] | ||||
Finance Lease Costs | $ 1 | $ 0 | $ 1 | $ 0 |
Leases - Other Information Rela
Leases - Other Information Related to Leases (Detail) - USD ($) $ in Millions | 6 Months Ended | |
Jun. 30, 2020 | Jun. 30, 2019 | |
Cash paid for amounts included in the measurement of lease liabilities: | ||
Operating cash flows from operating leases | $ 102 | $ 92 |
Right-of-use assets obtained in exchange for lease obligations: | ||
Operating leases | 75 | 28 |
Finance leases | $ 119 | $ 0 |
Weighted Average Remaining Lease Term: | ||
Operating leases | 4 years 9 months 7 days | 5 years 2 months 19 days |
Finance leases | 24 years 6 months | |
Weighted Average Discount Rate: | ||
Operating leases | 4.11% | 4.26% |
Finance leases | 3.18% |
Leases - Future Minimum Lease P
Leases - Future Minimum Lease Payments Under Non-cancellable Leases (Detail) - USD ($) $ in Millions | Jun. 30, 2020 | Dec. 31, 2019 |
Operating Leases | ||
Remainder of 2020 | $ 86 | |
2021 | 148 | |
2022 | 124 | |
2023 | 95 | |
2024 | 66 | |
2025 | 53 | |
Thereafter | 43 | |
Total future minimum lease payments | 615 | |
Less imputed interest | (59) | |
Total | 556 | |
Other current liabilities | 154 | |
Operating lease liabilities | 402 | $ 396 |
Total | 556 | |
Finance Leases | ||
Remainder of 2020 | 0 | |
2021 | 0 | |
2022 | 6 | |
2023 | 6 | |
2024 | 6 | |
2025 | 6 | |
Thereafter | 159 | |
Total future minimum lease payments | 183 | |
Less imputed interest | (63) | |
Total | 120 | |
Other liabilities | 120 | |
Total | $ 120 |
Goodwill - Summary of Goodwill
Goodwill - Summary of Goodwill by Reportable Segment (Detail) $ in Millions | 6 Months Ended |
Jun. 30, 2020USD ($) | |
Goodwill | |
Beginning balance | $ 12,159 |
Business combinations | 70 |
Impact of foreign currency fluctuations and other | (96) |
Ending balance | 12,133 |
Technology & Analytics Solutions | |
Goodwill | |
Beginning balance | 10,374 |
Business combinations | 70 |
Impact of foreign currency fluctuations and other | (51) |
Ending balance | 10,393 |
Research & Development Solutions | |
Goodwill | |
Beginning balance | 1,646 |
Business combinations | 0 |
Impact of foreign currency fluctuations and other | (48) |
Ending balance | 1,598 |
Contract Sales & Medical Solutions | |
Goodwill | |
Beginning balance | 139 |
Business combinations | 0 |
Impact of foreign currency fluctuations and other | 3 |
Ending balance | $ 142 |
Derivatives - Summary of Fair V
Derivatives - Summary of Fair Values of Derivative Instruments Designated as Hedges (Detail) - USD ($) | Jun. 30, 2020 | Dec. 31, 2019 |
Derivatives, Fair Value | ||
Derivatives | $ 1,000,000 | $ 4,000,000 |
Derivative liability fair value | 65,000,000 | 30,000,000 |
Derivatives designated as hedging instruments: | Other current assets and liabilities | Foreign exchange forward contracts | ||
Derivatives, Fair Value | ||
Derivatives | 1,000,000 | 4,000,000 |
Derivative liability fair value | 3,000,000 | 0 |
Derivative notional amount | 114,000,000 | 148,000,000 |
Derivatives designated as hedging instruments: | Other assets and liabilities | Interest rate swaps | ||
Derivatives, Fair Value | ||
Derivatives | 0 | 0 |
Derivative liability fair value | 60,000,000 | 27,000,000 |
Derivative notional amount | 1,800,000,000 | 875,000,000 |
Derivatives not designated as hedging instruments: | Other liabilities | Interest rate swaps | ||
Derivatives, Fair Value | ||
Derivatives | 0 | 0 |
Derivative liability fair value | 2,000,000 | 3,000,000 |
Derivative notional amount | $ 326,000,000 | $ 325,000,000 |
Derivatives - Effect of Cash Fl
Derivatives - Effect of Cash Flow Hedging Instruments on Other Comprehensive (Loss) Income (Detail) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2020 | Jun. 30, 2019 | |
Derivative Instruments and Hedging Activities Disclosures | ||||
Effect of cash flow hedging instruments on other comprehensive (loss) income | $ (10) | $ (20) | $ (39) | $ (28) |
Foreign exchange forward contracts | ||||
Derivative Instruments and Hedging Activities Disclosures | ||||
Effect of cash flow hedging instruments on other comprehensive (loss) income | 0 | (5) | (6) | (4) |
Interest rate derivatives | ||||
Derivative Instruments and Hedging Activities Disclosures | ||||
Effect of cash flow hedging instruments on other comprehensive (loss) income | $ (10) | $ (15) | $ (33) | $ (24) |
Derivatives - Additional Inform
Derivatives - Additional Information (Detail) $ in Millions | Jun. 30, 2020USD ($) |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
Foreign exchange loss related to net investment hedge | $ 8 |
Fair Value Measurements - Addit
Fair Value Measurements - Additional Information (Detail) - USD ($) $ in Millions | Jun. 30, 2020 | Dec. 31, 2019 |
Level 1 and Level 2 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis | ||
Fair value of total debt | $ 12,135 | $ 11,925 |
Fair Value Measurements - Fair
Fair Value Measurements - Fair Value of Financial Assets and Liabilities Measured on Recurring Basis (Detail) - USD ($) $ in Millions | Jun. 30, 2020 | Dec. 31, 2019 |
Assets: | ||
Marketable securities | $ 73 | $ 62 |
Derivatives | 1 | $ 4 |
Recurring Fair Value Measurements | ||
Assets: | ||
Marketable securities | 101 | |
Derivatives | 1 | |
Total | 102 | |
Liabilities: | ||
Derivatives | 65 | |
Contingent consideration | 111 | |
Total | 176 | |
Recurring Fair Value Measurements | Level 1 | ||
Assets: | ||
Marketable securities | 101 | |
Total | 101 | |
Recurring Fair Value Measurements | Level 2 | ||
Assets: | ||
Derivatives | 1 | |
Total | 1 | |
Liabilities: | ||
Derivatives | 65 | |
Total | 65 | |
Recurring Fair Value Measurements | Level 3 | ||
Liabilities: | ||
Contingent consideration | 111 | |
Total | $ 111 |
Fair Value Measurements - Chang
Fair Value Measurements - Changes in Level 3 Financial Assets and Liabilities Measured on Recurring Basis (Detail) - Contingent consideration - USD ($) $ in Millions | 6 Months Ended | |
Jun. 30, 2020 | Jun. 30, 2019 | |
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation | ||
Beginning balance | $ 113 | $ 123 |
Business combinations | 28 | 29 |
Contingent consideration paid | (17) | (39) |
Revaluations included in earnings and foreign currency translation adjustments | (13) | (5) |
Ending balance | $ 111 | $ 108 |
Fair Value Measurements - Key A
Fair Value Measurements - Key Assumptions (Details) | Jun. 30, 2020 |
Revenue target | |
Fair Value Measurement Inputs and Valuation Techniques | |
Weighted average probability of target achievement | 86.00% |
Revenue target | Minimum | |
Fair Value Measurement Inputs and Valuation Techniques | |
Range of potential payment | 0.00% |
Revenue target | Maximum | |
Fair Value Measurement Inputs and Valuation Techniques | |
Range of potential payment | 100.00% |
EBITDA target | |
Fair Value Measurement Inputs and Valuation Techniques | |
Weighted average probability of target achievement | 96.00% |
EBITDA target | Minimum | |
Fair Value Measurement Inputs and Valuation Techniques | |
Range of potential payment | 0.00% |
EBITDA target | Maximum | |
Fair Value Measurement Inputs and Valuation Techniques | |
Range of potential payment | 100.00% |
Operational target | |
Fair Value Measurement Inputs and Valuation Techniques | |
Weighted average probability of target achievement | 97.00% |
Operational target | Minimum | |
Fair Value Measurement Inputs and Valuation Techniques | |
Range of potential payment | 0.00% |
Operational target | Maximum | |
Fair Value Measurement Inputs and Valuation Techniques | |
Range of potential payment | 100.00% |
Credit Arrangements - Summary o
Credit Arrangements - Summary of Credit Facilities (Detail) | 6 Months Ended | |
Jun. 30, 2020USD ($) | Jun. 30, 2020GBP (£) | |
Receivables financing facility due 2022—U.S. Dollar LIBOR at average floating rates of 1.06% | ||
Line of Credit Facility | ||
Interest Rates | LIBOR Market Index Rate (0.16% at June 30, 2020) plus 0.90% | |
Rate (percent) | 0.16% | 0.16% |
Facility | $ 25,000,000 | |
Receivables financing facility due 2022—U.S. Dollar LIBOR at average floating rates of 1.06% | LIBOR | ||
Line of Credit Facility | ||
Interest rate spread on base rate (percent) | 0.90% | |
General Banking Facility | ||
Line of Credit Facility | ||
Interest Rates | Bank’s base rate of 0.10% at June 30, 2020 plus 1% | |
Rate (percent) | 0.10% | 0.10% |
Facility | $ 12,000,000 | £ 10,000,000 |
General Banking Facility | Base Rate | ||
Line of Credit Facility | ||
Interest rate spread on base rate (percent) | 1.00% | |
Revolving Credit Facility | ||
Line of Credit Facility | ||
Interest Rates | LIBOR in the relevant currency borrowed plus a margin of 1.50% at June 30, 2020 | |
Facility | $ 1,500,000,000 | |
Revolving Credit Facility | LIBOR | ||
Line of Credit Facility | ||
Rate (percent) | 1.50% | 1.50% |
Credit Arrangements - Summary_2
Credit Arrangements - Summary of Debt (Detail) € in Millions, $ in Millions | 6 Months Ended | ||
Jun. 30, 2020USD ($) | Jun. 24, 2020EUR (€) | Dec. 31, 2019USD ($) | |
Senior Secured Credit Facilities: | |||
Principal amount of debt | $ 12,181 | $ 11,705 | |
Less: unamortized discount and debt issuance costs | (74) | (60) | |
Less: unamortized discount and debt issuance costs | (142) | (100) | |
Long-term debt | $ 11,965 | 11,545 | |
Revolving Credit Facility | LIBOR | |||
Senior Secured Credit Facilities: | |||
Rate (percent) | 1.50% | ||
Receivables financing facility due 2022—U.S. Dollar LIBOR at average floating rates of 1.06% | |||
Senior Secured Credit Facilities: | |||
Rate (percent) | 0.16% | ||
Due in 2028 | 2.875 Senior Notes | |||
Senior Secured Credit Facilities: | |||
Principal amount of debt | € | € 711 | ||
Rate (percent) | 2.875% | ||
U.S Dollars | Due in 2023 | Revolving Credit Facility | LIBOR | |||
Senior Secured Credit Facilities: | |||
Principal amount of debt | $ 0 | 154 | |
Average floating rate | 1.66% | ||
U.S Dollars | Due in 2023 | Senior Secured Term A Loan | LIBOR | |||
Senior Secured Credit Facilities: | |||
Principal amount of debt | $ 749 | 770 | |
Average floating rate | 1.81% | ||
U.S Dollars | Due in 2023 | Term A Loan due 2023—U.S. Dollar LIBOR at average floating rates of 2.75% | LIBOR | |||
Senior Secured Credit Facilities: | |||
Principal amount of debt | $ 789 | 0 | |
Average floating rate | 2.75% | ||
U.S Dollars | Due in 2024 | Senior Secured Term B Loan | LIBOR | |||
Senior Secured Credit Facilities: | |||
Principal amount of debt | $ 535 | 535 | |
Average floating rate | 2.50% | ||
U.S Dollars | Due in 2025 | Senior Secured Term B Loan | LIBOR | |||
Senior Secured Credit Facilities: | |||
Principal amount of debt | $ 729 | 733 | |
Average floating rate | 1.93% | ||
U.S Dollars | Due in 2025 | Senior Secured Additional Term B Loan | LIBOR | |||
Senior Secured Credit Facilities: | |||
Principal amount of debt | $ 931 | 936 | |
Average floating rate | 2.06% | ||
U.S Dollars | Due in 2027 | 5.0% Senior Notes | |||
Senior Secured Credit Facilities: | |||
Principal amount of debt | $ 1,100 | 1,100 | |
Rate (percent) | 5.00% | ||
U.S Dollars | Due in 2026 | 5.0% Senior Notes | |||
Senior Secured Credit Facilities: | |||
Principal amount of debt | $ 1,050 | 1,050 | |
Rate (percent) | 5.00% | ||
U.S Dollars | Due in 2022 | Receivables financing facility due 2022—U.S. Dollar LIBOR at average floating rates of 1.06% | LIBOR | |||
Senior Secured Credit Facilities: | |||
Principal amount of debt | $ 300 | 300 | |
Rate (percent) | 1.06% | ||
EUR Dollars | Due in 2023 | Senior Secured Term A Loan | LIBOR | |||
Senior Secured Credit Facilities: | |||
Principal amount of debt | $ 377 | 387 | |
Average floating rate | 1.50% | ||
EUR Dollars | Due in 2024 | Senior Secured Term B Loan | LIBOR | |||
Senior Secured Credit Facilities: | |||
Principal amount of debt | $ 1,300 | 1,306 | |
Average floating rate | 2.00% | ||
EUR Dollars | Due in 2024 | 3.5% Senior Notes due 2024—Euro denominated | |||
Senior Secured Credit Facilities: | |||
Principal amount of debt | $ 0 | 701 | |
Rate (percent) | 3.50% | ||
EUR Dollars | Due in 2025 | Senior Secured Additional Term B Loan | LIBOR | |||
Senior Secured Credit Facilities: | |||
Principal amount of debt | $ 642 | 644 | |
Average floating rate | 2.00% | ||
EUR Dollars | Due in 2025 | 2.875 Senior Notes | |||
Senior Secured Credit Facilities: | |||
Principal amount of debt | $ 472 | 471 | |
Rate (percent) | 2.875% | ||
EUR Dollars | Due in 2025 | 3.25% Senior Notes due 2025—Euro denominated | |||
Senior Secured Credit Facilities: | |||
Principal amount of debt | $ 1,600 | 1,598 | |
Rate (percent) | 3.25% | ||
EUR Dollars | Due in 2025 | 3.5% Senior Notes due 2024—Euro denominated | |||
Senior Secured Credit Facilities: | |||
Rate (percent) | 3.50% | ||
EUR Dollars | Due in 2028 | 2.875 Senior Notes | |||
Senior Secured Credit Facilities: | |||
Principal amount of debt | $ 798 | 0 | |
Rate (percent) | 2.875% | ||
EUR Dollars | Due in 2028 | 2.25% Senior Notes due 2028—Euro denominated | |||
Senior Secured Credit Facilities: | |||
Principal amount of debt | $ 809 | 808 | |
Rate (percent) | 2.25% | ||
Japan, Yen | Revolving Credit Facility | LIBOR | |||
Senior Secured Credit Facilities: | |||
Principal amount of debt | $ 0 | $ 212 | |
Average floating rate | 1.50% |
Credit Arrangements - Contractu
Credit Arrangements - Contractual Maturities of Long-term Debt (Detail) - USD ($) $ in Millions | Jun. 30, 2020 | Dec. 31, 2019 |
Debt Disclosure [Abstract] | ||
Remainder of 2020 | $ 71 | |
2021 | 145 | |
2022 | 445 | |
2023 | 1,684 | |
2024 | 1,812 | |
Thereafter | 8,024 | |
Principal amount of debt | $ 12,181 | $ 11,705 |
Credit Arrangements - Additiona
Credit Arrangements - Additional Information (Detail) € in Millions | Jun. 24, 2020EUR (€) | Jun. 23, 2020 | Mar. 30, 2020USD ($) | Jun. 30, 2020USD ($) | Jun. 30, 2020GBP (£) | Jun. 30, 2020GBP (£) | Mar. 11, 2020USD ($) | Dec. 31, 2019USD ($) |
Line of Credit Facility | ||||||||
Outstanding borrowings | $ 12,181,000,000 | $ 11,705,000,000 | ||||||
Standby Letters of Credit | ||||||||
Line of Credit Facility | ||||||||
Available borrowing capacity | 1,500,000,000 | |||||||
Revolving Credit Facility | ||||||||
Line of Credit Facility | ||||||||
Aggregate maximum principal amount | $ 1,500,000,000 | |||||||
Revolving Credit Facility | LIBOR | ||||||||
Line of Credit Facility | ||||||||
Debt instrument interest rate stated percentage | 1.50% | 1.50% | ||||||
General Banking Facility | ||||||||
Line of Credit Facility | ||||||||
Bank guarantees | $ 1,100,000 | £ 900,000 | ||||||
Aggregate maximum principal amount | $ 12,000,000 | £ 10,000,000 | ||||||
Debt instrument interest rate stated percentage | 0.10% | 0.10% | ||||||
Senior Secured Credit Facilities | ||||||||
Line of Credit Facility | ||||||||
Aggregate maximum principal amount | $ 7,600,000,000 | |||||||
Outstanding borrowings | 6,100,000,000 | |||||||
Available borrowing capacity | 1,500,000,000 | |||||||
Senior Secured Credit Facilities | Revolving Credit Facility | ||||||||
Line of Credit Facility | ||||||||
Current borrowing capacity | 1,500,000,000 | |||||||
TLA - 2 Loans | Secured Debt | ||||||||
Line of Credit Facility | ||||||||
Aggregate maximum principal amount | $ 900,000,000 | |||||||
Prepaid debt | $ 100,000,000 | |||||||
TLA - 2 Loans | Secured Debt | LIBOR | ||||||||
Line of Credit Facility | ||||||||
Basis spread floor | 1.00% | |||||||
TLA - 2 Loans | Secured Debt | LIBOR | Minimum | ||||||||
Line of Credit Facility | ||||||||
Interest rate spread on base rate (percent) | 1.50% | |||||||
TLA - 2 Loans | Secured Debt | LIBOR | Maximum | ||||||||
Line of Credit Facility | ||||||||
Interest rate spread on base rate (percent) | 2.25% | |||||||
2.875 Senior Notes | Due in 2028 | ||||||||
Line of Credit Facility | ||||||||
Outstanding borrowings | € | € 711 | |||||||
Debt instrument interest rate stated percentage | 2.875% | |||||||
Debt instrument, frequency of periodic payment | semiannually | |||||||
2.875 Senior Notes | Due in 2028 | EUR Dollars | ||||||||
Line of Credit Facility | ||||||||
Outstanding borrowings | $ 798,000,000 | 0 | ||||||
Debt instrument interest rate stated percentage | 2.875% | 2.875% | ||||||
2.875 Senior Notes | Minimum | Due in 2028 | ||||||||
Line of Credit Facility | ||||||||
Redemption premium percentage | 0.00% | |||||||
2.875 Senior Notes | Maximum | Due in 2028 | ||||||||
Line of Credit Facility | ||||||||
Redemption premium percentage | 1.438% | |||||||
3.5% Senior Notes due 2024—Euro denominated | Due in 2024 | EUR Dollars | ||||||||
Line of Credit Facility | ||||||||
Outstanding borrowings | $ 0 | $ 701,000,000 | ||||||
Debt instrument interest rate stated percentage | 3.50% |
Stockholders' Equity - Narrativ
Stockholders' Equity - Narratives (Detail) - USD ($) $ / shares in Units, $ in Millions | 3 Months Ended | 6 Months Ended | |||
Mar. 31, 2020 | Jun. 30, 2019 | Mar. 31, 2019 | Jun. 30, 2020 | Dec. 31, 2019 | |
Class of Stock | |||||
Preferred stock, authorized (shares) | 1,000,000 | ||||
Preferred stock, par value (usd per share) | $ 0.01 | ||||
Preferred stock, shares issued (shares) | 0 | 0 | |||
Preferred stock, shares outstanding (shares) | 0 | 0 | |||
Repurchase of stock, value | $ 332 | $ 236 | $ 145 | ||
Equity Repurchase Under Repurchase Program | |||||
Class of Stock | |||||
Equity available for repurchase under the repurchase program | $ 1,000 | ||||
Secondary Public Offering | Equity Repurchase Under Repurchase Program | |||||
Class of Stock | |||||
Repurchase of stock (shares) | 2,106,403 | ||||
Repurchase of stock, value | $ 321.4 | ||||
Repurchased From Company Stockholders | Equity Repurchase Under Repurchase Program | |||||
Class of Stock | |||||
Repurchase of stock (shares) | 1,000,000 | ||||
Repurchase of stock, value | $ 164.3 |
Restructuring - Summary of Amou
Restructuring - Summary of Amounts Recorded for Restructuring Plans (Detail) $ in Millions | 6 Months Ended |
Jun. 30, 2020USD ($) | |
Restructuring Reserve | |
Restructuring reserves, beginning balance | $ 67 |
Expense, net of reversals | 30 |
Payments | (38) |
Foreign currency translation and other | (2) |
Restructuring reserves, ending balance | 57 |
Severance and Related Costs | |
Restructuring Reserve | |
Restructuring reserves, beginning balance | 64 |
Expense, net of reversals | 30 |
Payments | (37) |
Foreign currency translation and other | (2) |
Restructuring reserves, ending balance | 55 |
Facility Exit Costs | |
Restructuring Reserve | |
Restructuring reserves, beginning balance | 3 |
Expense, net of reversals | 0 |
Payments | (1) |
Foreign currency translation and other | 0 |
Restructuring reserves, ending balance | $ 2 |
Income Taxes - Narratives (Deta
Income Taxes - Narratives (Detail) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | 12 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2020 | Jun. 30, 2019 | Dec. 31, 2019 | |
Income Tax Disclosure [Abstract] | |||||
Effective income tax rate (percent) | 20.00% | 10.30% | 15.60% | 26.20% | |
Tax impact of share-based compensation awards | $ 5 | $ 8 | $ 26 | $ 17 | |
Discrete tax expense | $ 10 | ||||
Tax benefit recorded in 2019 | $ 20 |
Comprehensive Income (Loss) - S
Comprehensive Income (Loss) - Summary of Components of AOCI (Detail) | 6 Months Ended |
Jun. 30, 2020USD ($) | |
Statement of Other Comprehensive Income | |
Beginning balance | $ 6,003,000,000 |
Reclassification adjustments | 4,000,000 |
Ending balance | 5,591,000,000 |
Beginning balance | 156,000,000 |
Other comprehensive income (loss) before reclassifications | 17,000,000 |
Other comprehensive income (loss) before reclassifications | (137,000,000) |
Reclassification adjustments, tax | (1,000,000) |
Ending balance | 172,000,000 |
Foreign Currency Translation | |
Statement of Other Comprehensive Income | |
Beginning balance | (430,000,000) |
Other comprehensive income (loss) before reclassifications | (111,000,000) |
Ending balance | (541,000,000) |
Derivative Instruments | |
Statement of Other Comprehensive Income | |
Beginning balance | (21,000,000) |
Other comprehensive income (loss) before reclassifications | (43,000,000) |
Reclassification adjustments | 5,000,000 |
Ending balance | (59,000,000) |
Defined Benefit Plans | |
Statement of Other Comprehensive Income | |
Beginning balance | (16,000,000) |
Ending balance | (16,000,000) |
Accumulated Other Comprehensive (Loss) Income | |
Statement of Other Comprehensive Income | |
Beginning balance | (311,000,000) |
Ending balance | $ (444,000,000) |
Comprehensive Income (Loss) -_2
Comprehensive Income (Loss) - Summary of Adjustments for (Gains) Losses Reclassified from AOCI into Condensed Consolidated Statements of Income and Affected Financial Statement Line Item (Detail) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2020 | Jun. 30, 2019 | |
Reclassification Adjustment out of Accumulated Other Comprehensive Income | ||||
Total before income taxes | $ (11) | $ (3) | $ 5 | $ (5) |
Income tax (benefit) expense | 1 | 0 | 1 | (1) |
Total net of income taxes | (12) | (3) | 4 | (4) |
Foreign exchange forward contracts | Revenues | ||||
Reclassification Adjustment out of Accumulated Other Comprehensive Income | ||||
Total before income taxes | 3 | 0 | 5 | 1 |
Foreign exchange forward contracts | Other expense (income), net | ||||
Reclassification Adjustment out of Accumulated Other Comprehensive Income | ||||
Total before income taxes | $ (14) | $ (3) | $ 0 | $ (6) |
Segments - Additional Informati
Segments - Additional Information (Detail) | 6 Months Ended |
Jun. 30, 2020Segment | |
Segment Reporting [Abstract] | |
Number of reportable segments | 3 |
Segments - Operations by Report
Segments - Operations by Reportable Segments (Detail) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2020 | Jun. 30, 2019 | |
Segment Reporting Information | ||||
Revenues | $ 2,521 | $ 2,740 | $ 5,275 | $ 5,424 |
Costs of revenue, exclusive of depreciation and amortization | 1,704 | 1,799 | 3,528 | 3,547 |
Selling, general and administrative expenses | 431 | 436 | 838 | 855 |
Segment profit | 449 | 562 | 996 | 1,118 |
Depreciation and amortization | (308) | (294) | (624) | (589) |
Restructuring costs | (16) | (14) | (30) | (26) |
Income from operations | 62 | 197 | 255 | 407 |
Technology & Analytics Solutions | ||||
Segment Reporting Information | ||||
Revenues | 1,109 | 1,102 | 2,226 | 2,177 |
Costs of revenue, exclusive of depreciation and amortization | 655 | 656 | 1,321 | 1,289 |
Segment profit | 276 | 258 | 544 | 516 |
Research & Development Solutions | ||||
Segment Reporting Information | ||||
Revenues | 1,235 | 1,435 | 2,676 | 2,851 |
Costs of revenue, exclusive of depreciation and amortization | 898 | 971 | 1,886 | 1,917 |
Segment profit | 162 | 288 | 430 | 577 |
Contract Sales & Medical Solutions | ||||
Segment Reporting Information | ||||
Revenues | 177 | 203 | 373 | 396 |
Costs of revenue, exclusive of depreciation and amortization | 151 | 172 | 321 | 341 |
Segment profit | 11 | 16 | 22 | 25 |
Operating Segments | Technology & Analytics Solutions | ||||
Segment Reporting Information | ||||
Selling, general and administrative expenses | 178 | 188 | 361 | 372 |
Operating Segments | Research & Development Solutions | ||||
Segment Reporting Information | ||||
Selling, general and administrative expenses | 175 | 176 | 360 | 357 |
Operating Segments | Contract Sales & Medical Solutions | ||||
Segment Reporting Information | ||||
Selling, general and administrative expenses | 15 | 15 | 30 | 30 |
Corporate | ||||
Segment Reporting Information | ||||
Selling, general and administrative expenses | 63 | 57 | 87 | 96 |
Segment profit | $ (63) | $ (57) | $ (87) | $ (96) |
Earnings Per Share - Summary of
Earnings Per Share - Summary of Weighted-Average Outstanding Stock-Based Awards Excluded from Computation of Diluted Earnings Per Share (Detail) - shares shares in Millions | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2020 | Jun. 30, 2019 | |
Antidilutive Securities Excluded from Computation of Earnings Per Share | ||||
Total shares excluded from diluted earnings per share | 6.2 | 2.4 | 2.6 | 2.1 |
Shares subject to performance conditions | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share | ||||
Total shares excluded from diluted earnings per share | 1.1 | 1.3 | 1.2 | 1.3 |
Shares subject to anti-dilutive stock-based awards | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share | ||||
Total shares excluded from diluted earnings per share | 1.8 | 1.1 | 1.4 | 0.8 |
Dilutive shares excluded from dilutive earnings per share | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share | ||||
Total shares excluded from diluted earnings per share | 3.3 | 0 | 0 | 0 |